M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Evaluation of the Anti-CD-33 Immunotoxin Hum-195/rGel in Patients With Advanced Myeloid Malignancies

Phase 1

Completed

Conditions: Acute Myeloid Leukemia
Chronic Myelomonocytic Leukemia
Myeloproliferative Disorders
Anemia, Refractory, With Excess of Blasts

Interventions: Drug: Hum-195/rGel

First Posted Date: 2002-05-27

Last Posted Date: 2013-04-04

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 28

Registration Number: NCT00038051

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Assessment of Head and Neck Tumor Hypoxia Using 18F-Fluoromisonidazole

Not Applicable

Withdrawn

Conditions: Squamous Cell Carcinoma
Head and Neck Neoplasms
Metastases, Neoplasm

Interventions: Drug: 18F-fluoromisonidazole
Procedure: PET scan

First Posted Date: 2002-05-27

Last Posted Date: 2012-08-01

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT00038038

Locations: 🇺🇸
University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States

PEG-Intron For Chronic Myelogenous Leukemia Patients Unresponsive To Or Intolerant Of Roferon Or Intron

Phase 2

Terminated

Conditions: Leukemia, Myeloid, Philadelphia-Positive

Interventions: Drug: PEG-Intron

First Posted Date: 2002-05-27

Last Posted Date: 2018-11-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 1

Registration Number: NCT00037882

Locations: 🇺🇸
M. D. Anderson Cancer Center, Houston, Texas, United States

High Dose I-131 Metaiodobenzylguanidine(MIBG) for Metastatic Neuroendocrine Tumors

Phase 3

Completed

Conditions: Neuroendocrine Tumors
Metastases, Neoplasm

Interventions: Drug: I-131 Metaiodobenzylguanidine

First Posted Date: 2002-05-27

Last Posted Date: 2018-10-31

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 15

Registration Number: NCT00037869

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignancies

Phase 2

Completed

Conditions: Cutaneous T-cell Lymphoma
Chronic Lymphocytic Leukemia
Peripheral T-cell Lymphoma

Interventions: Drug: Deoxycoformycin (DCF)

First Posted Date: 2002-05-27

Last Posted Date: 2018-11-16

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 60

Registration Number: NCT00038025

Locations: 🇺🇸
M. D. Anderson Cancer Center, Houston, Texas, United States

Iodine I-131 Iodocholesterol, Its Use in Adrenal Screening

Phase 3

Completed

Conditions: Adrenal Gland Diseases
Adrenal Gland Neoplasms

First Posted Date: 2002-05-24

Last Posted Date: 2012-02-22

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 114

Registration Number: NCT00037843

Locations: 🇺🇸
University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States

Safety, Efficacy and Pharmacokinetic Between Capecitabine and Exisulind in Metastatic Breast Cancer Patients

Phase 1

Completed

Conditions: Breast Neoplasms
Metastases, Neoplasm

Interventions: Drug: Capecitabine
Drug: Exisulind

First Posted Date: 2002-05-20

Last Posted Date: 2012-10-24

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 35

Registration Number: NCT00037609

Locations: 🇺🇸
University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States

Clofarabine in Chronic Lymphocytic Leukemia

Phase 1

Completed

Conditions: Hematologic Neoplasms
Lymphoproliferative Disorders
Leukemia
Leukemia, Lymphocytic, Chronic

First Posted Date: 2002-01-09

Last Posted Date: 2015-03-25

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 100

Registration Number: NCT00028418

Locations: 🇺🇸
University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy